Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon3.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-HERC4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
HERC4 also known as HECT and RLD domain-containing E3 ubiquitin protein ligase 4 is a protein that mechanically functions as an E3 ubiquitin ligase. Weighing approximately 120 kDa HERC4 facilitates the transfer of ubiquitin from E2 ubiquitin-conjugating enzymes to substrate proteins tagging them for degradation by the proteasome. The protein is expressed in various tissues including the brain heart and lung indicating its broad functional significance across different biological systems.
Biological function summary
HERC4 plays an important role in regulating protein turnover and cellular processes. As part of the ubiquitin-proteasome system it ensures protein quality control and homeostasis by targeting misfolded or damaged proteins. While HERC4 does not traditionally form complexes its activity influences the stability and function of other proteins within the cell. This implicates HERC4 in not only cellular maintenance but also processes such as cell cycle regulation and signal transduction.
Pathways
The ubiquitin-proteasome pathway involves HERC4 contributing to the degradation of regulatory proteins that control various cellular activities. The protein interacts with pathways like cell cycle progression and stress response. It maintains a functional relationship with proteins such as p53 a known tumor suppressor and other E3 ligases that manage the proteolytic balance in the cell demonstrating its integration into critical regulatory networks.
HERC4 has connections to cancer and neurodegenerative diseases. In cancer aberrant ubiquitination activities involving HERC4 can disrupt normal protein regulation leading to uncontrolled cell growth. It may interact with oncogenic proteins that escape degradation promoting tumor progression. In neurodegenerative disorders such as Parkinson's disease dysregulation of the ubiquitin-proteasome system potentially involving HERC4 connects with proteins like Parkin impacting neuronal survival and function. Understanding HERC4's role in these pathways provides insights into potential therapeutic targets for these conditions.
